Mark W. Begor - Nov 1, 2023 Form 4 Insider Report for EQUIFAX INC (EFX)

Signature
/s/Lisa Stockard as Attorney-in-Fact
Stock symbol
EFX
Transactions as of
Nov 1, 2023
Transactions value $
-$1,166,037
Form type
4
Date filed
11/2/2023, 04:03 PM
Previous filing
Oct 18, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EFX Common Stock Sale -$14.9K -88 -0.13% $168.88 69.9K Nov 1, 2023 Direct F1, F2, F3
transaction EFX Common Stock Sale -$247K -1.48K -2.12% $166.92 68.4K Nov 1, 2023 Direct F1, F3, F4
transaction EFX Common Stock Sale -$248K -1.5K -2.2% $165.07 66.9K Nov 1, 2023 Direct F1, F3, F5
transaction EFX Common Stock Sale -$315K -1.87K -2.8% $168.39 65.1K Nov 1, 2023 Direct F1, F3, F6
transaction EFX Common Stock Sale -$340K -2.05K -3.16% $165.68 63K Nov 1, 2023 Direct F1, F3, F7
holding EFX Common Stock 20K Nov 1, 2023 2-Year 2022 GRAT
holding EFX Common Stock 69.4K Nov 1, 2023 2-Year 2023 GRAT
holding EFX Common Stock 13.5K Nov 1, 2023 2-year May 2022 GRAT
holding EFX Common Stock 23.1K Nov 1, 2023 4-Year 2021 GRAT
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/17/2023.
F2 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.805 to $169.14, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F3 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.
F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $166.565 to $167.53, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $164.35 to $165.34, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F6 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $167.76 to $168.73, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F7 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $165.35 to $166.24, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.